©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Regulation of Cellular Cholesterol Efflux by Lecithin:Cholesterol Acyltransferase Reaction through Nonspecific Lipid Exchange (*)

(Received for publication, July 26, 1995)

Helena Czarnecka Shinji Yokoyama (§)

From the Lipid and Lipoprotein Research Group and Department of Medicine, The University of Alberta, Edmonton, Alberta T6G 2S2, Canada

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Erythrocyte was found lacking in reactivity to lipid-free apolipoproteins to generate pre-beta-high density lipoprotein (HDL) with the cellular lipid and, therefore, was used to study cellular cholesterol efflux to plasma lipoproteins exclusively by a nonspecific exchange mechanism. Over the range of hematocrit from 1-20% (cellular cholesterol pool of 2.5 µg to 50 µg per 250 µl), the fractional rate of cellular cholesterol efflux to lipoprotein was constant, and, therefore, absolute efflux rate was a linear function of the hematocrit of this range. In the absence of lecithin:cholesterol acyltransferase (LCAT), the cholesterol influx rate from lipoproteins was equal to the efflux rate from erythrocyte resulting in no net transfer of cholesterol, with either HDL or low density lipoprotein. In the presence of LCAT in the mixture of HDL and erythrocyte, cholesterol was esterified exclusively in HDL regardless of the origin. When the hematocrit was low and efflux of cellular cholesterol was slower than cholesterol esterification, the esterification of cell-originating cholesterol did not directly enhance the efflux. With high hematocrit that gives faster cholesterol efflux, the efflux was increased directly by the cholesterol esterification. On the other hand, the LCAT reaction significantly reduced HDL-cholesterol influx. The LCAT reaction thus induces substantial net cholesterol efflux from erythrocytes through a nonspecific cholesterol exchange mechanism.


INTRODUCTION

Esterification of cholesterol in plasma by lecithin:cholesterol acyltransferase (LCAT) (^1)is believed to play a significant role in cellular cholesterol efflux. It maintains the gradient of cholesterol content between cellular and lipoprotein surfaces by reducing free cholesterol in lipoprotein, which is thought to generate continuous flow of cholesterol from cell to lipoprotein (Glomset, 1968). LCAT is known to act mainly on high density lipoprotein (HDL) (Akanuma and Glomset, 1968), and this is one of the reasons why HDL is believed to have a unique function for the efflux of cellular cholesterol.

Interestingly, experimental data to support this hypothesis has not been published so much as it is believed. The original work by Murphy (1962) demonstrated the net decrease of cholesterol in erythrocyte membrane by incubating the cells with plasma. Also, free cholesterol was shown to decrease in low density lipoprotein (LDL) as LCAT esterifies cholesterol in HDL (Akanuma and Glomset, 1968; Ko et al., 1994). However, many works using cultured cells failed to demonstrate direct enhancement of cellular cholesterol efflux by cholesterol esterification in HDL (Stein et al., 1978; Ray et al., 1980; Fielding and Fielding, 1981; Kilsdonk et al., 1993), while some of them showed the increase of net cellular cholesterol efflux by the LCAT reaction by reducing the influx of HDL cholesterol (Ray et al., 1980; Fielding and Fielding, 1981). Thus, a precise role of LCAT in the efflux of cellular cholesterol remains to be identified. This is related to the fact that a genetic defect of LCAT results in cholesterol accumulation only in a limited number of organs but not in general cholesterol deposit (Glomset et al., 1983).

Cellular cholesterol efflux is mediated by two distinct mechanisms. One is nonspecific exchange of cholesterol between the cell and lipoprotein surface (Hara and Yokoyama, 1992; Li et al., 1993), and the other is the reaction of lipid-free helical apolipoproteins with cellular surface to result in unidirectional removal of the cellular lipids and to generate new pre-beta-HDL particles with the cellular lipid (Hara and Yokoyama, 1991, 1992; Li et al., 1993). The cellular lipid efflux to HDL is likely to involve both mechanisms as HDL-apoproteins dissociate from the lipoprotein to interact with high affinity association sites of the cells (Li et al., 1993, 1995). We demonstrated the efficient esterification of cholesterol by LCAT in the pre-beta-HDL newly generated with the cellular phospholipid and cholesterol of macrophages and fibroblasts by lipid-free apolipoprotein (apo) A-I, but it did not enhance net cellular cholesterol efflux any further (Czarnecka and Yokoyama, 1995). Net cellular cholesterol efflux to HDL was increased by LCAT reaction only by decreasing the cholesterol influx from HDL to the cells while the efflux was not directly enhanced (Czarnecka and Yokoyama, 1995), in agreement with the results previously demonstrated by a few other authors (Ray et al., 1980; Fielding and Fielding, 1981).

In the work presented in this paper, we demonstrate that erythrocyte is lacking in the free apolipoprotein-mediated cellular lipid efflux. This means that cholesterol efflux from erythrocyte is by a nonspecific bidirectional movement exclusively. Therefore, the erythrocyte is a good model by which to study the factors including LCAT reaction that may affect cellular cholesterol efflux through a nonspecific cholesterol exchange mechanism. In addition, erythrocyte membrane in fact undergoes pathological change as one of a few symptoms of genetic LCAT deficiency (Glomset et al., 1983). Hence, we have chosen this cell to examine a role of LCAT reaction in cellular cholesterol efflux purely by nonspecific cholesterol exchange.

By using erythrocyte, the rate of cellular cholesterol efflux was easily modulated by changing the amount of the cells in the incubation mixture. When the cholesterol exchange rate was high, the LCAT reaction in HDL directly increased the efflux of cellular cholesterol toward HDL. When the exchange rate was low and the efflux rather than the esterification was a rate-limiting step, the increase of the net efflux was mainly by the decrease of the influx.


MATERIALS AND METHODS

LCAT, Lipoproteins, and Apolipoproteins

LCAT was isolated from pig plasma as described elsewhere to 16,000-fold (Czarnecka and Yokoyama, 1993). The protein of the preparation migrated as a single band of molecular mass 67,000 kDa by silver staining in electrophoresis in the presence of sodium dodecyl sulfate (SDS). Specific activity (V(max)) of the preparation was 18 nmol/µg/h for cholesterol esterification in the cholesterol-labeled HDL (below). LDL and HDL were isolated from fresh human plasma as a fraction of density 1.006-1.063 g/ml and 1.063-1.21 g/ml, respectively, and the purity was verified by lipoprotein electrophoresis in 0.5% agarose gel and by the analysis of apolipoprotein composition in polyacrylamide gel electrophoresis in the presence of SDS. HDL was treated with 10 mMN-ethylmaleimide at room temperature for 2 h in order to inactivate endogenous LCAT. Lipid composition of the lipoprotein preparation was analyzed by enzymatic assay methods (Table 1). Lipoprotein-cholesterol was labeled with either [4-^14C]cholesterol (Amersham, 53 mCi/mmol) or [7-^3H]cholesterol (Amersham, 23.3 Ci/mmol) by incubating LDL or HDL with the radiolabeled cholesterol in a complex with fatty acid-free bovine serum albumin (BSA) at 37 °C for 3 h (Czarnecka and Yokoyama, 1993). ApoA-I was purified further from human HDL as described elsewhere by delipidation with ether:ethanol (3:2) and anion exchange chromatography with DEAE-cellulose (Yokoyama et al., 1982). The purity was verified in polyacrylamide gel electrophoresis in SDS.



Erythrocyte

Erythrocytes were obtained from normal fresh human blood taken in 0.1% EDTA, being separated from plasma by centrifugation at 3000 times g at 4 °C and washed with minimum essential medium containing 14 mM HEPES, pH 7.4, three times. The cellular lipid composition was determined after lipid was extracted according to the method of Bligh and Dyer(1959) (Table 1). The cells were labeled with either [7-^3H]cholesterol or L-alpha-1-palmitoyl-2-[9,10-^3H]palmitoylphosphatidylcholine (Amersham, 60.0 Ci/mmol). The labeled lipid (17.1 nmol of cholesterol or 6.7 nmol of phosphatidylcholine) was dried in a glass tube with a nitrogen stream, redissolved in 60 µl of ethanol, and mixed with the washed erythrocytes in the solution of the washing buffer (24 ml, hematocrit 8.5%) containing 0.2% BSA for the incubation at room temperature for 24 h. The cells were then washed extensively with the same buffer. Specific radioactivity of each cellular lipid was determined. Erythrocytes were also obtained from a pig (approximately 100 kg) before and 1 week after bleeding of 1.0 liter. Reticulocytes were concentrated from the after-bleeding blood sample to the extent that 50-60% of the cells was the reticulocyte according to the method described previously (Kim et al., 1976) except for longer centrifugation at the final stage (3,500 rpm for 30 min). Both control erythrocytes from normal pig blood and the reticulocyte-enriched erythrocytes were used for the efflux experiments by the same method as employed for the human cells.

Cellular Cholesterol Efflux, Lipoprotein-Cholesterol Influx, and Esterification of Cholesterol

The radiolabeled erythrocytes were incubated with various amounts of apoA-I or unlabeled HDL in the presence of 0.1% BSA with and without LCAT at 37 °C in 250 µl, with continuous mixing. Hematocrit of the incubation mixture was chosen between 1 and 20% in order to provide various cellular cholesterol pool sizes. Activity of the LCAT in the mixture supernatant was 20% of that in the standard pooled human plasma, 10.8 nmol/ml/h (0.6 µg of LCAT/ml) unless specified otherwise. The incubation was terminated by placing the mixture in ice, and then erythrocytes were removed by centrifugation at 4 °C. Lipids in the supernatant were extracted according to the previous method (Bligh and Dyer, 1959) and analyzed by thin layer chromatography for cholesteryl ester, free cholesterol, and phosphatidylcholine. For measuring the influx of cholesterol from HDL to erythrocytes at the same time, the [4-^14C]cholesterol-labeled HDL was incubated with the [7-^3H]cholesterol-labeled erythrocytes in the absence and presence of LCAT, and the radioactivity of the lipid in the medium was determined by the same procedure. In the same experiment using the [4-^14C]cholesterol-labeled HDL and the [7-^3H]cholesterol-labeled erythrocyte, esterification of cholesterol on HDL was measured for each radioisotope by thin layer chromatography in order to determine the origin of cholesterol esterified by LCAT. The influx of free cholesterol from HDL or LDL was alternatively measured by using the lipoproteins labeled with [7-^3H]cholesterol and unlabeled erythrocytes.


RESULTS

Human erythrocyte was found lacking in the free apoA-I-mediated lipid efflux. Fig. 1shows the efflux of cellular cholesterol and phosphatidylcholine from erythrocyte induced by human HDL and lipid-free apoA-I in the condition of 16% hematocrit. Unlike many other cells in culture, no lipid efflux was induced by lipid-free apoA-I from erythrocyte. Thus, cholesterol efflux from erythrocyte induced by HDL is mediated only by nonspecific cholesterol exchange between the surfaces of the cell and HDL, and this makes it possible to study cellular cholesterol efflux without influence of the free apolipoprotein-mediated lipid efflux. The same experiment with pig erythrocytes and reticulocytes also showed the specific lack of the free apoA-I-induced cholesterol efflux (data not shown).


Figure 1: Lipid efflux from erythrocytes. The erythrocytes labeled either for cholesterol (A) or phosphatidylcholine (B) were incubated, as the 16% hematocrit, with various amount of HDL (triangles) or apoA-I (squares) in the mixture of 250 µl for 24 h at 37 °C. The efflux of cholesterol was calculated from its specific radioactivity in the labeled cells. The efflux of phospholipid was expressed as disintegrations/min per incubation mixture since the radiolabeled dipalmitoylphosphatidylcholine did not seem to represent a homogeneous exchangeable pool of cellular phospholipid. Each data point represents an average of the duplicated experiments.



When LCAT was present (0.6 µg) in the incubation mixture of HDL and [^3H]cholesterol-labeled erythrocytes, the enzyme esterified cholesterol whether cell-originating or HDL-originating (Fig. 2A). This particular experimental condition included 16% hematocrit (cellular cholesterol pool 40.4 µg), 50 µg of HDL-phospholipid, and 14.0 µg HDL-free cholesterol in 250 µl. Apparent percent esterification in HDL of cell-originating cholesterol was lower than that of HDL-originating cholesterol in the early phase of the radiolabeled cholesterol efflux, presumably due to the influx of HDL-free cholesterol to the erythrocytes and to the time lag caused by mixing of exogenous and endogenous cholesterol in HDL. At the 6-h incubation, percent esterification of cellular cholesterol in HDL was a function of the LCAT concentration in the medium (Fig. 2B). There was no cholesterol esterification by LCAT directly on erythrocytes in any of these experimental conditions (data not shown).


Figure 2: LCAT reaction in HDL in the incubation mixture with erythrocyte. The left panel (A) shows percent of esterified cholesterol in HDL at each incubation time. Squares indicate cholesterol originated in HDL represented by [^3H]cholesterol labeled in erythrocyte, and triangles indicate that originated in erythrocyte represented by [^14C]cholesterol labeled in HDL. Hematocrit was 16% and the free cholesterol pool of the HDL was 14 µg in 250 µl of the incubation mixture. Percentage of radioactivity in the esterified cholesterol was calculated against the total cholesterol radioactivity in the medium at each time point. Each data point represents the average of the two measurements. The right panel (B) demonstrates the LCAT-dose dependence of esterification of cell cholesterol at a 6-h incubation. Experimental conditions were the same as in A.



In the initial 1 h of the incubation of the same mixture with 16% hematocrit, the efflux and influx of radiolabeled cholesterol between HDL and erythrocyte were both linear, and the rates were nearly the same in the absence of LCAT (Fig. 3). The net efflux of cellular cholesterol was, therefore, almost negligible. Cholesterol esterification by LCAT (0.6 µg of LCAT in the mixture, 20% of the plasma LCAT activity in the medium) caused enhancement of cellular cholesterol efflux and reduction of HDL-cholesterol influx (Fig. 3). Thus, a substantial amount of net cholesterol efflux was generated by LCAT from erythrocytes to HDL. On the other hand, cholesterol was exchanged between erythrocytes and LDL (50 µg of phospholipid and 20.3 µg of free cholesterol) without causing net efflux. The rates were approximately the same as those with HDL in the absence of LCAT (Fig. 4). LCAT hardly esterified cholesterol in LDL causing no change of cholesterol flux (Fig. 4).


Figure 3: The initial phase of the cholesterol efflux from erythrocytes to HDL. [^3H]Cholesterol-labeled erythrocyte (16% hematocrit) was incubated with unlabeled HDL as 14.0 µg of free cholesterol (50 µg of phospholipid) at 37 °C in the absence and presence of LCAT as 20% of its plasma activity (0.6 µg) in the incubation mixture. The same experiment was done except for using [^3H]cholesterol-labeled HDL and unlabeled erythrocyte to observe the influx of HDL-free cholesterol. Each data point represents an average of triplicate experimental points with an error bar for the standard error. A and B represent the efflux experiment in the absence and presence of LCAT, respectively. The shadowed area represents free cholesterol, and the hatched area represents esterified cholesterol in the medium. C represents the influx experiment with and without LCAT (diamonds and squares, respectively). An asterisk indicates p < 0.05 against the counterpart without LCAT.




Figure 4: The initial phase of the cholesterol efflux from erythrocytes to LDL. [^3H]Cholesterol-labeled erythrocyte (16% hematocrit) was incubated with unlabeled LDL 20.3 µg of as free cholesterol (50 µg of phospholipid) at 37 °C in the presence and absence of LCAT as 20% of its plasma activity (0.6 µg). The same experiment was done except for using [^3H]cholesterol-labeled LDL and unlabeled erythrocyte to observe the influx of LDL-free cholesterol. Each data point represents an average of triplicate experimental points with an error bar for the standard error. A and B represent the efflux experiments in the absence and presence of LCAT, respectively. The shadowed area represents free cholesterol in the medium. Squares and diamonds in C represent the influx of LDL-free cholesterol in the absence and presence of LCAT, respectively.



The effect of LCAT reaction on cellular cholesterol efflux was also observed in long time incubation in the mixture of 16% hematocrit (cellular cholesterol pool 40.4 µg) and HDL-free cholesterol pool (1.7 µg). In the absence of LCAT, the cholesterol efflux was rapid and the radiolabeled cholesterol efflux reached nearly steady state equilibrium with back influx in a few hours (Fig. 5A). The influx of HDL cholesterol is reciprocal to the cellular cholesterol efflux reaching the steady state in the same time course (Fig. 5C). When LCAT was present (20% of the plasma activity), the cellular cholesterol efflux was prominently increased particularly in the late phase, and the increment was as much as the cholesterol esterified (Fig. 5B). The influx of HDL cholesterol was decreased by the LCAT reaction, again more markedly in the late phase (Fig. 5C). As a consequence, the net efflux of cellular cholesterol was negligible in the absence of LCAT and was induced substantially by the LCAT reaction (Fig. 6). These data are in contrast to the previous observation with the cells in culture that there was no increase of cellular cholesterol efflux but only a significant decrease of HDL-cholesterol influx by LCAT (Ray et al., 1980; Fielding and Fielding, 1981; Czarnecka and Yokoyama, 1995).


Figure 5: Entire time course of cholesterol flux between erythrocytes and HDL and the effect of the LCAT reaction. [^3H]Cholesterol-labeled erythrocytes were incubated with [^14C]cholesterol-labeled HDL in the presence and absence of LCAT. Hematocrit was 16%, HDL-free cholesterol was 1.7 µg, and the LCAT activity in the medium was 20% of its activity (0.6 µg) in plasma in 250 µl of the incubation mixture. A and B represent the efflux of cellular cholesterol measured by the increase of [^3H]cholesterol in the medium in the absence and presence of LCAT, respectively. The shadowed area represents free cholesterol, and the hatched area represents esterified cholesterol in the medium. C represents the influx of HDL cholesterol to the cells measured by the decrease of [^14C]cholesterol in the medium. The diamonds and squares represent presence and absence of LCAT in the mixture, respectively. Each data point represents an average of the triplicate experiments with a standard error.




Figure 6: Net cholesterol efflux from erythrocytes to HDL. The data were calculated from the experiment shown in Fig. 5, as the difference between the efflux and influx at each experimental point. Diamonds represent the data with LCAT, and squares represent the data without LCAT.



We hypothesized that rate of the cellular cholesterol efflux is a determining factor for the direct effect of LCAT on the efflux. To test this hypothesis, the efflux rate was manipulated by changing the hematocrit of the incubation mixtures having a constant amount of HDL (50 µg of phospholipid and 14.0 µg of free cholesterol), and the effect of the LCAT reaction on the efflux was examined in each condition. Fig. 7represents the reactions with the hematocrit of 1%, 5%, and 15%, in the presence and absence of 0.6 µg of LCAT (20% of its activity in plasma). The rate of esterification of HDL-originating cholesterol was approximately 4.7 nmol/h in this experimental condition being estimated from the data in Fig. 2(percent esterification) and Fig. 3(influx of HDL-free cholesterol).


Figure 7: The efflux of cellular cholesterol to HDL from various hematocrits of erythrocytes. HDL (14 µg of free cholesterol and 50 µg of phospholipid) was incubated with [^3H]cholesterol-labeled erythrocytes as 1, 5, and 15% hematocrit (Ht). Cellular choline-phospholipid was 3.4 µg, 17.5 µg, and 52.7 µg, and cellular cholesterol was 2.5 µg, 12.6 µg, and 37.9 µg, respectively, in the incubation mixture. Each data point represents an average of the duplicate experiments. The shadowed area represents free cholesterol, and the hatched area represents esterified cholesterol.



With the lowest hematocrit of 1%, cellular free cholesterol was about 2.5 µg, and this was equivalent to that of many similar experiments using the cells in culture. In this condition, efflux rate of radiolabeled cholesterol was in the same order as the rate from the cells in culture. As shown in the top panels of Fig. 7, the labeled cholesterol in the medium almost linearly increased up to 24 h indicating that the efflux did not reach the steady state equilibrium with the back influx within this incubation time. There was no increase of the cholesterol efflux by cholesterol esterification by LCAT (the top right panel of Fig. 7). The rate of the labeled cholesterol efflux increased as the hematocrit increased. The efflux was reaching the steady state equilibrium with the back influx within the same time range (the middle and lower panels of Fig. 7). The cholesterol esterification in HDL induced significant increases of the efflux in this condition (the lower right panel). The increment of the efflux by LCAT reached the same extent as the amount of esterified cholesterol with the 15% hematocrit.

Further analysis was attempted for the data with various cellular cholesterol pools including those shown in Fig. 8. The rate of the cellular cholesterol efflux was estimated from the initial rate of the radiolabeled cholesterol efflux from the erythrocytes (calculated as a least square linear regression of the efflux data for the initial 2 h). The top panel demonstrates that the rate of the cholesterol efflux from erythrocyte is almost directly proportional to the cellular cholesterol pool size in the incubation mixture, showing that the fractional efflux rate of cellular cholesterol (percent of the cellular cholesterol pool) was constant over the range of the experimental condition. The lower panel shows that such increases of the rate of the cholesterol efflux (the x axis) resulted in higher increases of the cholesterol efflux by cholesterol esterification in HDL (the y axis). When the hematocrit is above 15%, the rate of the cholesterol efflux (6.2 nmol/h) would be as high as the esterification rate (4.7 nmol/h) (estimated from the data in Fig. 2and Fig. 7). The increment of the efflux by LCAT seemed to reach the same extent as that of cholesterol esterification in such a condition.


Figure 8: Analysis of the relationship between erythrocyte cholesterol pool size and the rate of cholesterol efflux from erythrocytes to HDL, and of that among the efflux rate, the increment of the efflux, and relative cholesterol esterification in HDL. The top panel (A) shows a linear increase of the cellular cholesterol efflux rate without cholesterol esterification as a function of cellular cholesterol pool size. The rate was calculated as an average of the slope in the initial part of the time course of the radiolabeled cellular cholesterol efflux (up to 2 h) of at least four individual experimental points using the data presented in Fig. 7. The bottom panel (B) shows the increment of the efflux by cholesterol esterification (squares) and relative cholesterol esterification (as ester/free cholesterol) (circles) as a function of the rate of the cellular cholesterol efflux calculated in the top panel. The efflux increment and relative esterification were calculated by using the data of the incubation of 6 and 24 h presented in Fig. 7. The error bars represent standard error.




DISCUSSION

Erythrocyte in peripheral blood, including reticulocyte, was shown to have no interaction with lipid-free helical apolipoproteins to generate pre-beta-HDL with the cellular lipids. Therefore, cholesterol transfer between erythrocytes and plasma lipoproteins is exclusively by a nonspecific exchange mechanism. Cholesterol efflux rate from erythrocytes to HDL depended directly on the cellular cholesterol pool size. Without LCAT reaction, the efflux and influx rates between erythrocyte and HDL were the same, and no net flux was generated. Net cholesterol efflux was induced when LCAT esterified cholesterol in HDL. When the efflux (exchange) was slower than cholesterol esterification, a direct increase of the efflux by LCAT was not apparent, and the net cholesterol efflux was caused mainly by the reduction of cholesterol influx from HDL to the cells. When the cholesterol exchange was faster than the esterification, it directly caused the increase of cellular cholesterol efflux.

Specific lack of the reactivity to lipid-free apolipoprotein in erythrocyte has provided additional evidence that apolipoprotein-mediated cellular lipid efflux is an independent pathway of nonspecific cholesterol exchange. Erythrocytes seem to lose the interaction with helical apolipoproteins perhaps during the maturation in an earlier stage than reticulocyte, and, accordingly, it does not provide a direct lipid source for generation of new HDL in blood. By using erythrocytes, therefore, cellular cholesterol efflux can be studied without the influence of the apolipoprotein-cell interaction. It is also possible to make the cellular cholesterol pool in the experimental incubation mixture much larger than that of the cultured cells by more than an order of the magnitude. Accordingly, this system simulates a physiological condition in the bloodstream where HDL and erythrocyte interact directly in solution. Using cells in culture may not exactly mimic an in vivo microenvironment for the interaction of lipoprotein with the cells in tissues, in terms of the local density of cell membrane and its cholesterol pool size exposed to lipoproteins in the adjacent interstitial fluid.

LCAT has been known to play a role in regulation of the net cholesterol efflux from erythrocyte. In his classical work, Murphy(1962) demonstrated the decrease of cholesterol in erythrocytes by incubating with plasma. It is also known that cholesterol accumulates in a limited number of organs in the patient with genetic or secondary LCAT deficiencies (Glomset et al., 1983; Simon and Scheig, 1970), and erythrocyte is one of the primary organs where such cholesterol accumulation takes place. These data implicate that lipid of erythrocyte membrane undergoes the direct influence of plasma lipoprotein metabolism as one of the major cholesterol reservoirs in blood (Mindham and Mayes, 1991).

The results of this study showed that HDL removes cholesterol from erythrocytes only in the presence of LCAT. When cholesterol is esterified in HDL, the influx of cholesterol from HDL to the cell is reduced as the free cholesterol in HDL decreases. However, the efflux is not increased directly by the LCAT reaction when its rate is slower than the esterification (Czarnecka and Yokoyama, 1995). The off-rate of the cellular cholesterol efflux is presumably a rate-limiting step in such a condition so that additional room for free cholesterol in HDL created by the cholesterol esterification cannot immediately be filled with cell cholesterol due to the slow efflux. Thus, a condition such as 1% hematocrit is equivalent to most of the in vitro experiments using the cells in culture, with respect to the cellular cholesterol pool size and the rate of the cellular cholesterol efflux. The rate of cellular cholesterol efflux increased in proportion to the cellular cholesterol pool size, and the efflux of radiolabeled cellular cholesterol rapidly reached a steady state equilibrium with the back influx. In such a condition, esterification of cholesterol by LCAT in HDL has caused a direct increase of the appearance of cellular cholesterol in HDL as a consequence of this rapid exchange rate.

Thus, LCAT regulates cellular cholesterol efflux through a nonspecific exchange mechanism. As it esterifies cholesterol in HDL, the rate of cholesterol influx from HDL to cells is reduced significantly. The LCAT reaction directly increases the efflux of cellular cholesterol when the rate of cholesterol exchange between HDL and the cells is faster than cholesterol esterification.

Cholesterol accumulation varies over various organs in the patients with genetic or secondary defects of LCAT, resulting in a pathological change in a limited number of the organs (Glomset et al., 1983; Simon and Scheig, 1970). From the conclusion of this study, it can be speculated that the tissues lacking in a free apolipoprotein-mediated cellular lipid efflux pathway are more severely affected by LCAT deficiency because the LCAT-dependent nonspecific pathway is the only available mechanism to remove cholesterol from such tissues. Erythrocyte, and perhaps cornea as well, seems to be such a case since these cells may not synthesize the new protein required for the cells to interact with helical apolipoproteins. Other tissues are capable of shedding cholesterol via the apolipoprotein-mediated pathway even without the help of LCAT. It is also conceivable that the tissues having a slow rate of cholesterol exchange with HDL may be less affected by the deficiency of LCAT since the contribution to net cell cholesterol removal of the LCAT-mediated efflux is small.

This paper demonstrated that LCAT actively regulates cholesterol content of erythrocytes in the bloodstream. The question is whether this conclusion can be extrapolated to other tissues where the exchange rate of cholesterol between the cells and HDL is yet to be determined. Recently, Francis et al.(1995) reported that fibroblasts from homozygous Tangier disease patients (genetic HDL deficiency) showed specific and complete defect of the apolipoprotein-mediated cellular cholesterol efflux pathway. Therefore, cholesterol removal from the peripheral tissues is carried out only by the LCAT-dependent nonspecific mechanism in these patients. Interestingly, cholesterol esterification in the plasma of these patients is not drastically reduced in spite of their extremely low plasma HDL level (Clifton-Bligh et al., 1972; Ohtaki et al., 1983), and the accumulation of cholesterol is limited only in certain organs related to the reticuloendothelial system (Schaefer et al., 1980). Therefore, the LCAT-mediated net cellular cholesterol removal seems active and efficient through nonspecific cholesterol exchange in the tissues of many organs. Thus, together with the finding in the LCAT deficiency, we conclude that the two distinct mechanisms to induce net cellular cholesterol efflux back each other up in most of the tissues.

A role of HDL in net cellular cholesterol efflux thus seems to be dual. One is to carry helical apolipoproteins that dissociate from HDL and interact directly with cellular surface to remove the cellular lipid by generating new pre-beta-HDL. LCAT does not play a significant role in this pathway (Czarnecka and Yokoyama, 1995). The other role of HDL is to provide the site for LCAT reaction to induce the net cholesterol efflux by reducing the influx of cholesterol from HDL to the cells and by increasing the efflux of cellular cholesterol through nonspecific cholesterol exchange.


FOOTNOTES

*
This work was supported by Operating Grant MT11764 from Medical Research Council of Canada, operating grants from the Heart and Stroke Foundation of Alberta, and by a research fund provided by Sankyo Co. Ltd. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Lipid and Lipoprotein Research Group and Department of Medicine, 332 Heritage Medical Research Centre, The University of Alberta, Edmonton, Alberta T6G 2S2, Canada. Tel.: 403-492-2963; Fax: 403-492-3383; :syokoyam{at}gpu.srv.ualberta.ca.

(^1)
The abbreviations used are: LCAT, lecithin:cholesterol acyltransferase; HDL, high density lipoprotein; LDL, low density lipoprotein; apo, apolipoprotein; BSA, bovine serum albumin.


ACKNOWLEDGEMENTS

We thank Dr. Janeal Mick and Dr. Artur Cegielski of R. D. SinClair Research Centre, Dept. of Agricultural, Food and Nutritional Science, The University of Alberta, for their contribution to the preparation of pig erythrocytes and reticulocytes. We also thank Lisa Main for her technical support.


REFERENCES

  1. Akanuma, Y., and Glomset, J. (1968) J. Lipid Res. 9, 620-626 [Abstract/Free Full Text]
  2. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911-917
  3. Clifton-Bligh, P., Nestel, P. J., and Wyhte, H. M. (1972) N. Engl. J. Med. 286, 567-571 [Medline] [Order article via Infotrieve]
  4. Czarnecka, H., and Yokoyama, S. (1993) J. Biol. Chem. 268, 19334-19340 [Abstract/Free Full Text]
  5. Czarnecka, H., and Yokoyama, S. (1995) Biochemistry 34, 4385-4392 [Medline] [Order article via Infotrieve]
  6. Fielding, C. J., and Fielding P. E. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 3911-3914 [Abstract]
  7. Francis, G. A., Knopp, R. H., and Oram, J. F. (1995) J. Clin. Invest. 96, 78-87 [Medline] [Order article via Infotrieve]
  8. Glomset, J. A. (1968) J. Lipid Res. 9, 155-167 [Abstract/Free Full Text]
  9. Glomset, J. A., Norum, K. R., and Gjone, E. (1983) in The Metabolic Basis of Inherited Disease (Stanbury, J. B., Wyngaarden, J. B., Fredrickson, D. S., Goldstein, J. L., and Brown, M. S., eds) 5th Ed., pp. 643-654, McGraw-Hill, New York
  10. Hara, H., and Yokoyama, S. (1991) J. Biol. Chem. 266, 3080-3086 [Abstract/Free Full Text]
  11. Hara, H., and Yokoyama, S. (1992) Biochemistry 31, 2040-2046 [Medline] [Order article via Infotrieve]
  12. Kilsdonk, E. P. C., Dorsman, A. N. R. D., and van Tol, A. (1993) Int. J. Biochem. 25, 219-221 [Medline] [Order article via Infotrieve]
  13. Kim, H. D., Luthra, M. G., Hildenbrandt, G. R., and Zeidler, R. B. (1976) Am. J. Physiol. 230, 1676-1682 [Medline] [Order article via Infotrieve]
  14. Ko, K. W. S., Ohnishi, T., and Yokoyama, S. (1994) J. Biol. Chem. 269, 28206-28213 [Abstract/Free Full Text]
  15. Li, Q., Komaba, A., Hara, H., and Yokoyama, S. (1993) Biochemistry 32, 4597-4603 [Medline] [Order article via Infotrieve]
  16. Li, Q., Czarnecka, H., and Yokoyama, S. (1995) Biochim. Biophys. Acta 1259, 227-234 [Medline] [Order article via Infotrieve]
  17. Mindham, M. A., and Mayes, P. A. (1991) Biochem. J. 279, 503-508 [Medline] [Order article via Infotrieve]
  18. Murphy, J. R. (1962) J. Lab. Clin. Med. 60, 86-109
  19. Ohtaki, S., Nakagawa, H., Kida, N., Nakamura, H., Tsuda, K., Yokoyama, S., Yamamura, T., Tajima, S., and Yamamoto, A. (1983) Atherosclerosis 49, 79-88 [Medline] [Order article via Infotrieve]
  20. Ray, E., Bellini, F., Stoudt, G., Hemperly, S., and Rothblat, G. (1980) Biochim. Biophys. Acta 617, 318-334 [Medline] [Order article via Infotrieve]
  21. Schaefer, E. J., Zech, L. A., Schwartz, D. E., and Brewer, H. B. (1980) Ann. Int. Med. 93, 261-266 [Medline] [Order article via Infotrieve]
  22. Simon, J. B., and Scheig, R. (1970) New Engl. J. Med. 283, 841-846 [Medline] [Order article via Infotrieve]
  23. Stein, O., Goren, R., and Stein Y. (1978) Biochim. Biophys. Acta 529, 309-318 [Medline] [Order article via Infotrieve]
  24. Yokoyama, S., Tajima, S., and Yamamoto, A. (1982) J. Biochem. (Tokyo) 91, 1267-1272 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.